Key Documents

NIH Biosketch available Online

Curriculum Vitae available Online

Richard B. Moss

Professor - Med Center Line, Pediatrics - Pulmonary Medicine

Contact Information

Clinical Offices

Respiratory Specialties and ENT 730 Welch Rd 1st Floor Palo Alto, CA 94304
Telephone Work (650) 497-8841 Fax (650) 497-8791
Academic Offices

Personal Information
Email rmoss@stanford.edu Tel (650) 723-5191, (650) 723-5223

Administrative Contact
Eleilda Ayala Administrative Associate Email eleildaa@stanford.edu Tel Work 650-723-5191

Not for medical emergencies or patient use

Clinical Focus

Allergy/Asthma/Immunology, Pediatric
Pulmonary Medicine/Cystic Fibrosis, Pediatric
Allergy and Immunology

Administrative Appointments

Chief, Allergy-Immunology, Pediatrics, Stanford University , (2005– present )
Chief, Allergy-Immunology, Pediatrics, Stanford University , (1991– 1996 )
Chief, Pediatric Pulmonology, Stanford University , (1991– 2006 )
Director, Cystic Fibrosis Center, Stanford University , (1991– present )
Principal Investigator, CF Therapeutics Development Network Center, Stanford University , (1999– present )
Chair, Protocol Review Committee, Cystic Fibrosis Therapeutic Development Network, Cystic Fibrosis Foundation , (2002– 2005 )
Director, Allergy-Immunology Fellowship Training Program, Stanford University-UCSF , (2006– present )
Co-Director, Children's Health Research Program, Stanford University Medical Center-Lucile Packard Children's Hospital , (2006– present )

Honors and Awards

Provider of the Year, Cystic Fibrosis Foundation, N. Cal chapter (2008)
Best Doctors in America, Best Doctors (2001-2009)
America's Top Pediatricians-Pulmonology, Consumers Research Council of America (2002-2006)
Professional of the Year, Cystic Fibrosis Research, Inc. (2003)
Member, American Pediatric Society (2005)
Who's Who in America, Marquis (2006)

Professional Education

Board Certification: Diagnostic Laboratory Immunology, American Board of Allergy and Immunology (1986)
Board Certification: Allergy and Immunology, American Board of Allergy and Immunology (1981)
Board Certification: General Pediatrics, American Board of Pediatrics (1981)
SUMC - Graduate Medical Education (1981) CA
Northwestern University (1977) IL
Children's Memorial Hospital (1976) IL
SUNY Downstate Medical Center (1975) NY
BA, Columbia University Political Science (1971)
MD, SUNY Downstate Med Center NYC Medicine (1975)

Graduate & Fellowship Program Affiliations

Community & International Work

Project/Grant reviewer More »
Scientific Advisory Board More »

Web Site Links

Stanford Center for Excellence in Pulmonary Biology

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities.

Consulting: Genentech, MPEX, Novartis

Research Interests

I am interested in the pathogenesis of chronic airways diseases of childhood. My work includes basic and clinical research. In the area of basic research, my laboratory has focused on immunoregulation of inflammation in cystic fibrosis, finding deficiencies of activated T cells from CF patients in production of counter-regulatory cytokines (IL-10, IFN-gamma) and redox metabolism. In the arena of clinical research, as a member of the CFF Therapeutics Development Network our research group conducts many trials. I have particular interests in the areas of aerosol therapy with drugs, biologics and gene vectors; mechanisms of pulmonary inflammation and immunomodulatory therapy; and corrrection of CFTR-dependent cell biology defects. We are also investigating new treatments for CF complications such as diabetes and osteoporosis, internet-based disease management, and trials of asthma drugs.

Clinical Trials

Cystic Fibrosis Registry Recruiting
EPIC Clinical Study Recruiting
Gilead FTI Study Recruiting
Inspire Open-Label Extension study Recruiting
Vertex 770-102 Study Recruiting
Vertex 809-101 study Recruiting
#5901 Primary Ciliary Dyskinesia Study Recruiting
#5902 Rare Genetic Disorders Study Recruiting
HOLA CF Study Recruiting
ISIS Study Recruiting
KaloBios Recruiting
Mpex 204 Phase 2 Recruiting
NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients Recruiting
EPIC Observational Study No longer recruiting
GSK - SB656933 No longer recruiting
Inspire Phase 3: INS37217 Completed
Inspire Tiger 2 No longer recruiting
Vertex Phase 2a: VX-770 No longer recruiting
Altus Phase 3: ALTU-135 No longer recruiting

Publications

VX-770, a Novel CFTR Potentiator, in Cystic Fibrosis Patients with the G551D Mutation Accurso FJ, Clancy JP, Rowe SM, Boyle MP, Dunitz J, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein R, Uluer AZ, Aitken ML, Freedman SD, Dong Q, Zha J, Stone AJ, Olson ER, Ordonez CL, Campbell PW, Ashlock MA, Ramsey BW. submitted.
High frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular disease: an exploratory randomized controlled trial Yuan N, Kane P, Shelton K, Matel J, Becker B, Moss RB. J Child Neurol, accepted..
Allergic bronchopulmonary aspergillosis Moss RB, eCysticFibrosis Review (http://www.hopkinscme.net/ofp/eCysticFibrosisReview/index.html). 2010;
Ahead of the Curve - Emerging CF Therapies. Pathophysiology and Therapeutic Targets. Moss RB, Johns Hopkins Advanced Studies in Medicine.. 2010; In press.
Allergic bronchopulmonary aspergillosis Moss RB, In Latge JP, Steinbach WJ, Eds. Aspergillus Fumigatus and Aspergillosis. ASM Press. 2009; 332-350
Highlights of a workshop to discuss targeting inflammation in cystic fibrosis Banner K, De Jonge H, Elborn S, Growcott E, Gulbins E, Konstan M, Moss R, Poll C, Randell SH, Rossi AG, Thomas. J Cystic Fibrosis. 2009; 8 (1): 1-9
Infection, inflammation and the downward spiral of cystic fibrosis lung disease Moss RB, Journal of Pediatrics. 2009; 154 162-163
Cystic fibrosis HRCT scores correlate strongly with Pseudomonas infection. Robinson TE, Leung AN, Chen X, Moss RB, Emond MJ. Pediatr Pulmonol. 2009; 44 (11): 1107-17
Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs Makam M, Diaz D, Gernez Y, Conrad CK, Dunn CE, Moss RB, Herzenberg LA, Herzenberg LA, Tirouvanziam R. Proceed Natl Acad Sci USA. 2009; 106 5779-5783
The role of fungi in chronic airways infection Moss RB, Commentaries on Chronic Airway Infection. 2008; 2 (14): 2-8
Profound functional and signalling changes in viable neutrophils homing to cystic fibrosis airways Tirouvanziam R, Gernez Y, Conrad CK, Moss RB, Schrijver I, Dunn CE, Davies ZA, Herzenberg LA, Herzenberg LA. Proceed Natl Acad Sci USA. 2008; 105 4335-4339
Management of allergic aspergillosis Moss RB, Current Fungal Infection Reports. 2008; 2 87-93
Chest imaging in cystic fibrosis Robinson TE, Moss RB. Commentaries on Chronic Airway Infection. 2008; 2 (3): 2-8
No detectable improvements in CFTR by nasal aminoglycosides in CF patients heterozygous for stop mutations. Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson RL, Zeitlin P, Berclaz Y, Moss R, Knowles M, Oster RA, Mayer-Ham. Am J Resp Molec Cell Biol. 2007; 37 57-66
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Gibson RL, Emerson J, Hamblett N, Burns JL, McNamara S, Accurso F, Konstan MW, Chatfield BA, Retsch-Bogart G, W. Pediatric Pulmonology. 2007; 42 610-623
Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J. Human Gen Ther. 2007; 18 726-732
Aggressive treatment strategies in the fight against cystic fibrosis Mogayzel PJ, Clancy JP, Moss RB, Johns Hopkins Advanced Studies in Medicine. 2007; 7 (14): 426-458
Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O'Rourke A, Konstan MW, Wagener J, Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann CM, Aitken ML, Mahl TC, Young KR, Dunitz J, Murray FT. Pancreas. 2006; 32 (3): 258-63
High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. Proc Natl Acad Sci U S A. 2006; 103 (12): 4628-33
The urokinase type plasminogen activator system in induced sputum of patients with asthma Wang L, Xiao W, Moss RB, Hsu YP. Chinese J TB Resp Dis. 2006; 29 124-7
Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA. Kurup VP, Knutsen AP, Moss RB, Bansal N. Clin Molec Allergy. 2006; 4 (1): 11 [EPub]
Gene therapy for cystic fibrosis: the rise and fall of a viral vector Moss RB, US Respiratory Disease. 2006; 40
Pathophysiology and immunology of allergic bronchopulmonary aspergillosis. Moss RB, Med Mycol. 2005; 43 Suppl 1 S203-6
Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Moss RB., Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K.. Pediatr Pulmonol. 2005; 39 (3): 209-18
Aspergillus antigens and immunodiagnosis of allergic bronchopulmonary aspergillosis. Kurup VP, Knutsen AP, Moss RB.. In Kurup VS, Ed. Mold Allergy, Biology and Pathogenesis. Research Signpost.. 2005; 37/661 (2): 137-146
Fungal allergy in cystic fibrosis Moss RB, Kurup VS, Ed. Mold Allergy, Biology and Pathogenesis. Research Signpost.. 2005; 37/661 (2): 93-104
Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F, Moss RB. Chest. 2005; 128 (4): 2327-35
Fully automated system for three-dimensional bronchial morphology analysis using volumetric multidetector computed tomography of the chest Venkatraman R, Raman R, Raman B, Moss RB, Rubin GD, Mathers LH, Robinson TE. J Digital Imaging. 2005; Dec 13 Epub
Diagnostic testing by comprehensive mutation analysis in a large group of Hispanics: novel mutations and assessment of a population-specific mutation spectrum Schrijver I, Ramalingam S, Sankaran R, Swanson S, Dunlop CLM, Keiles S, Wassman EF, Moss R, Oehlert J, Gardner P, Kammesheidt.. J Molec Diagnostics. 2005; 7 (2): 289-99
Novel contributions to the Asian CFTR mutation spectrum: genotype and phenotype in Thai patients with cystic fibrosis. Schrijver I, Karnsakul W, Ramalingam S, Sankaran R, Moss R, Gardner P. Am J Med Genet. 2005; 133 103-5.
Sputum cathelicidin, plasmin activation system components and cytokine patterns discriminate cystic fibrosis, chronic obstructive pulmonary disease and asthma from each other and healthy subjects Xiao W, Hsu YP, Ishizaka A, Kirikae, Moss RB. Chest. 2005; 28 2316-2326
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE. Chest. 2004; 125 (2): 509-21
Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease. Bonnel AS, Song SM, Kesavarju K, Newaskar M, Paxton CJ, Bloch DA, Moss RB, Robinson TE. Pediatr Pulmonol. 2004; 38 (5): 396-405
Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. Moss RB, Clin Exp Immunol. 2004; 135 (3): 358-60
Inhalational antibiotics for airways infection Moss RB, Experimental Lung Research. 2004; 30 (Suppl 1): 58-61
Allergic bronchopulmonary aspergillosis with normal serum IgE in a child with cystic fibrosis Dorsaneo D, Borowitz D, Sharp J, Moss R. Ped Asthma Allergy Immunol. 2004; 17 146-150
Bloch EA, Germana J, Konstan M, Kuhn R, Llewellyn A, Moss R, Nickerson B, Rinker K, Sufian BS, VanDevanter D, Wagener J. Cystic Fibrosis: Treatment Practice Guidelines Pocket Guide. Professional Resources in Management Education, Inc. 2004;
AAV-CFTR gene therapy for cystic fibrosis: retrospect and prospect. Carter BJ, Munson K, Burstein H, Peluso R, Gerard C, Guggino W, Engelhardt J, Flotte T,Moss R.. Pediatric Pulmonology. 2003; Suppl 25 159-160
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B. Am J Respir Crit Care Med. 2003; 167 (6): 841-9
Advances against aspergillosis. Steinbach WJ, Stevens DA, Denning DW, Moss RB. Clin Infect Dis. 2003; 37 Suppl 3 S155-6
AAV-CFTR gene therapy for cystic fibrosis: retrospect and prospect Carter BJ, Munson K, Burstein H, Peluso R, Gerard C, Guggino W, Engelhardt J, Flotte T, Moss R. Pediatr Pulmonol. 2003; Suppl 25 159-60
Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease. Robinson TE, Leung AN, Northway WH, Blankenberg FG, Chan FP, Bloch DA, Holmes TH, Moss RB. Am J Respir Crit Care Med. 2003; 168 (5): 588-93
Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, Skov M, Maish W, Mastella G. Clin Infect Dis. 2003; 37 Suppl 3 S225-64
Cystic Fibrosis Foundation Consensus Conference recommendations on diagnosis and treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis: executive summary Moss RB, Stevens DA. CFF Consensus Conferences. 2003; X Sect 3
A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, Brown BW, Desch JK, Norbash AM, Conrad CK, Guggino WB, Flotte TR, Wine JJ, Carter BJ, Reynolds TC, Moss RB, Gardner P. Hum Gene Ther. 2002; 13 (11): 1349-59
Allergic bronchopulmonary aspergillosis. Moss RB, Clin Rev Allergy Immunol. 2002; 23 (1): 87-104
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Moss RB, Chest. 2002; 121 (1): 55-63
A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. Hum Gene Ther. 2001; 12 (15): 1907-16
Comprehensive mutation screening in a cystic fibrosis center. Wine JJ, Kuo E, Hurlock G, Moss RB. Pediatrics. 2001; 107 (2): 280-6
New approaches to cystic fibrosis. Moss RB, Hosp Pract (Minneap). 2001; 36 (1): 25-7, 31-2, 35-7
Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. Robinson TE, Leung AN, Northway WH, Blankenberg FG, Bloch DA, Oehlert JW, Al-Dabbagh H, Hubli S, Moss RB. J Pediatr. 2001; 138 (4): 553-9
Administration of aerosolized antibiotics in cystic fibrosis patients. Moss RB, Chest. 2001; 120 (3 Suppl): 107S-113S
Cystic fibrosis: new insights and treatments Moss RB, Hospital Practice, online at http://www.hosppract.com/issues/2001/01/moss.htm. 2001; 25-37
Cystic fibrosis: new insights and treatments Moss RB, Hospital Practice. 2001; 36 25-37
Novel Cystic Fibrosis mutation L1093P: functional analysis and possible Native American origin. Yee K, Robinson C, Hurlock G, Moss RB, Wine JJ. Hum Mutat. 2000; 15 (2): 208
Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Moss RB, Hsu YP, Olds L. Clin Exp Immunol. 2000; 120 (3): 518-25
Pulmonary sequelae of bronchopulmonary dysplasia survivors: high-resolution CT findings. Howling SJ, Northway WH, Hansell DM, Moss RB, Ward S, Müller NL. AJR Am J Roentgenol. 2000; 174 (5): 1323-6
Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies. Wagner JA, Nepomuceno IB, Shah N, Messner AH, Moran ML, Norbash AM, Moss RB, Wine JJ, Gardner P. J Gene Med. 1999 Jan-Feb; 1 (1): 13-21
Anti-arthropod saliva antibodies among residents of a community at high risk for Lyme disease in California. Lane RS, Moss RB, Hsu YP, Wei T, Mesirow ML, Kuo MM. Am J Trop Med Hyg. 1999; 61 (5): 850-9
Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Redding G, Rubio T, Williams-Warren J, Wilmott R, Wilson HD, Yogev R. J Pediatr. 1999; 134 (4): 413-21
Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Illek B, Zhang L, Lewis NC, Moss RB, Dong JY, Fischer H. Am J Physiol. 1999; 277 (4 Pt 1): C833-9
Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Nepomuceno IB, Esrig S, Moss RB. Chest. 1999; 115 (2): 364-70
Standardized high-resolution CT of the lung using a spirometer-triggered electron beam CT scanner. Robinson TE, Leung AN, Moss RB, Blankenberg FG, al-Dabbagh H, Northway WH. AJR Am J Roentgenol. 1999; 172 (6): 1636-8
Two novel mutations in a cystic fibrosis patient of Chinese origin. Wagner JA, Vassilakis A, Yee K, Li M, Hurlock G, Krouse ME, Moss RB, Wine JJ. Hum Genet. 1999; 104 (6): 511-5
Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P. Laryngoscope. 1999; 109 (2 Pt 1): 266-74
BioMedNet Interview 1 Oct 1999 Moss RB, HMS Beagle (on-line, site closed 30 June 2004). 1999;
Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials Wagner JA, Nepumuceno IB, Shah N, Messner AH, Moran ML, Norbash AM, Moss RB, Wine JJ, Gardner P. J Gene Med. 1999; 109 13-21
Chronic intermittment administration of inhaled tobramycin in patients with cystic fibrosis Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev M, et al for the Cystic Fibrosis Inhaled Tobramycin Study Group (member).. N Engl J Med. 1999; 340 23-30
Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus Wagner JA, Moran ML, Messner AH, Diafuku R, Kouyama D, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner. Laryngoscope. 1999; 109 266-74
Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. Bhudhikanok GS, Wang MC, Marcus R, Harkins A, Moss RB, Bachrach LK. J Pediatr. 1998; 133 (1): 18-27
A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Wagner JA, Moran ML, Messner AH, Daifuku R, Conrad CK, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P. Hum Gene Ther. 1998; 9 (6): 889-909
Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, Flotte TR, Gardner P. Lancet. 1998; 351 (9117): 1702-3
A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. Mickle JE, Macek M, Fulmer-Smentek SB, Egan MM, Schwiebert E, Guggino W, Moss R, Cutting GR. Hum Mol Genet. 1998; 7 (4): 729-35
A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems Eisenberg J, Aerosolized Tobramycin Study Group (member).. Chest. 1997; 1112 955-62
Activation of eosinophils in the airways of lung transplantation patients. Dosanjh AK, Elashoff D, Kawalek A, Moss RB, Esrig S. Chest. 1997; 112 (5): 1180-3
Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations Wilmott RW, Amin RS, Colin A, Devault A, Dozor AJ, Eigen H, Johnson C, Lester LA, McCoy K, McKean LP, Moss R, Nash ML, Pagel Jue C, Regelmann W, Stokes DC, Fuchs HJ. Am J Respir Crit Care Med. 1996; 153 1914-7
Correlates of osteopenia in patients with cystic fibrosis. Bhudhikanok GS, Lim J, Marcus R, Harkins A, Moss RB, Bachrach LK. Pediatrics. 1996; 97 (1): 103-11
Immune therapies for lung infection in cystic fibrosis Moss RB, IACFA Newsletter. 1996; 46 8-13
When to use a HEPA filter for atopic childhood asthma Moss RB, J Respir Dis. 1996; 17 806
Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna M, Wei T, Gardner P. Clin Exp Immunol. 1996; 106 (2): 374-88
Sinus disease in cystic fibrosis Light M, Moss RB, Davidson TM. Gershwin EM and Incaudo GA, Eds. Diseases of the Sinuses: A Comprehensive Textbook of Diagnosis and Treatment. Humana Press, Inc., Totowa NJ. 1995; 357-65
Inflammatory response in cystic fibrosis lung disease Moss RB, New Insights into Cystic Fibrosis. 1995; 324 1-6
Practice parameters for the diagnosis and treatment of asthma Spector SL, Nicklas RA, Joint Task Force on Practice Parameters (member).. J Allergy Clin Immunol. 1995; 96 707-870
Alternative pharmacotherapies for steroid-dependent asthma. Moss RB, Chest. 1995; 107 (3): 817-25
Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage. Reduction in recurrence requiring surgery. Moss RB, King VV. Arch Otolaryngol Head Neck Surg. 1995; 121 (5): 566-72
Activation of CFTR chloride current by nitric oxide in human T lymphocytes. Dong YJ, Chao AC, Kouyama K, Hsu YP, Bocian RC, Moss RB, Gardner P. EMBO J. 1995; 14 (12): 2700-7
Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Moss RB, Clin Infect Dis. 1995; 21 (4): 839-49; quiz 850-1
New drugs for cystic fibrosis lung disease. Moss RB, West J Med. 1995; 162 (4): 354-5
Outcome measures for clinical trials in cystic fibrosis Ramsey BW, Boat T, Accurso F, Bennett W, Boucher R, Brody A, Crystal R, Cutting G, Davis P, Dorkin H, Fleming T. Kaplan R, Knowles M, Konstan M, Laube B, McElvaney G, Morgan W, Moss R, Orenstein R, Pencharz P, Rosenstein B, Schidlow D, Smith A, Spino M, Stallings V, Stecenko A, Terrin M, Weatherly M, Wilmott R, Wilson C, Wood. J Pediatr. 1994; 124 177-92
Osteopenia in adults with cystic fibrosis. Bachrach LK, Loutit CW, Moss RB. Am J Med. 1994; 96 (1): 27-34
Aerosolized recombinant human DNase reduces respiratory exacerbations and improves pulmonary function in patients with cystic fibrosis Fuchs HJ, Borowitz DS, Christiansen DH, et al for the Pulmozyme® Study Group (member).. N Engl J Med. 1994; 331 637-42
Differential diagnosis of asthma in children Moss RB, Gershwin ME and Halpern GM, Eds. Bronchial Asthma. Principles of Diagnosis and Treatment, 3rd Ed, The Humana Press Inc., Totowa NJ. 1994; 141-69
Immunopathogenesis of cystic fibrosis lung disease Moss RB, Hillman B (ed). Pediatric Respiratory Diseases: Diagnosis and Treatment. W.B. Saunders, Philadelphia. 1993; 674-87
[Passive immunotherapy for treatment of endobronchitis in cystic fibrosis] Moss RB, Infusionsther Transfusionsmed. 1993; 20 Suppl 1 42-6; discussion 47
Pulmonary defenses Moss RB, Hillman B (ed). Pediatric Respiratory Diseases: Diagnosis and Treatment. W.B. Saunders, Philadelphia, Hillman B (ed). Pediatric Respiratory Diseases: Diagnosis and Treatment. W.B. Saunders, Philadelphia. 1993; 36-46
Sinusitis and polyposis in cystic fibrosis Moss RB, Druce HM, Ed. Sinusitis--Pathophysiology and Treatment. Marcel Dekker, New York. 1993; 247-81
Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys: II. A histopathologic analysis. Cheung AT, Moss RB, Kurland G, Leong AB, Novick WJ. J Med Primatol. 1993; 22 (4): 257-62
Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys: I. Effects of pentoxifylline on neutrophil influx. Cheung AT, Moss RB, Leong AB, Novick WJ. J Med Primatol. 1992 Sep-Oct; 21 (7-8): 357-62
Selective polysaccharide antibody deficiency in familial DiGeorge syndrome. Schubert MS, Moss RB. Ann Allergy. 1992; 69 (3): 231-8
Deficiency of IgG4 in children: association of isolated IgG4 deficiency with recurrent respiratory tract infection. Moss RB, Carmack MA, Esrig S. J Pediatr. 1992; 120 (1): 16-21
The role of sinus surgery in chronic sinusitis in children King VV, Moss RB. Am J Allergy Asthma Pediatr. 1992; 5 203-8
Gastroesophageal reflux-associated lung disease Moss RB, Prober CG, Behrman RE (eds). Nelson Self-Assessment in Pediatrics, CME Supplement Test No. ZN9212. 1992;
Drug allergy in cystic fibrosis. Moss RB, Clin Rev Allergy. 1991 Spring-Summer; 9 (1-2): 211-29
Evaluation of the immunologic cross-reactivity of aztreonam in patients with cystic fibrosis who are allergic to penicillin and/or cephalosporin antibiotics. Moss RB, McClelland E, Williams RR, Hilman BC, Rubio T, Adkinson NF. Rev Infect Dis. 1991 May-Jun; 13 Suppl 7 S598-607
Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. Moss RB, J Allergy Clin Immunol. 1991; 87 (1 Pt 1): 78-88
IgE antibodies in tick bite-induced anaphylaxis. Van Wye JE, Hsu YP, Lane RS, Terr AI, Moss RB. J Allergy Clin Immunol. 1991; 88 (6): 968-70
Anaphylaxis from a tick bite. Van Wye JE, Hsu YP, Terr AI, Moss RB, Lane RS. N Engl J Med. 1991; 324 (11): 777-8
Anaphylaxis from a tick bite Van Wye JE, Hsu YP, Lane RS, Terr AI, Moss RB. N Engl J Med. 1991; 324 777-8
Immunoglobulin G subclasses. Moss RB, West J Med. 1991; 154 (4): 458
Late pulmonary sequelae of bronchopulmonary dysplasia. Northway WH, Moss RB, Carlisle KB, Parker BR, Popp RL, Pitlick PT, Eichler I, Lamm RL, Brown BW. N Engl J Med. 1990; 323 (26): 1793-9
Drug allergy in cystic fibrosis Moss RB, Moss RB (ed). Cystic Fibrosis. Infection, Immunopathology, and Host Response. Humana Press, Clifton NJ. 1990; 211-29
Moss RB, Cystic Fibrosis. Infection, Immunopathology, and Host Response. Humana Press, Clifton NJ. 1990; 1-251
Antibody production in cystic fibrosis and possibilities for immunotherapy Moss RB, Pediatr Pulmonol. 1990; Suppl 5 66-7
Sinus disease in patients with severe cystic fibrosis: relation to pulmonary exacerbation. Umetsu DT, Moss RB, King VV, Lewiston NJ. Lancet. 1990; 335 (8697): 1077-8
Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. Van Wye JE, Collins MS, Baylor M, Pennington JE, Hsu YP, Sampanvejsopa V, Moss RB. Pediatr Pulmonol. 1990; 9 (1): 7-18
Bird fancier's disease in children Palmer J, Parker BR, Moss R, Lewiston NJ. Am J Asthma Allergy Pediatr. 1989; 3 45-52
Suppression of the late cutaneous response by immunotherapy. Fling JA, Ruff ME, Parker WA, Whisman BA, Martin ME, Moss RB, Reid MJ. J Allergy Clin Immunol. 1989; 83 (1): 101-9
Regarding article by Earl and Sullivan. Moss RB, J Allergy Clin Immunol. 1989; 83 (6): 1138
Allergic etiology and immunology of asthma. Moss RB, Ann Allergy. 1989; 63 (6 Pt 2): 566-77
Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. Eichler I, Joris L, Hsu YP, Van Wye J, Bram R, Moss R. J Clin Invest. 1989; 84 (6): 1794-804
Mountain cedar pollinosis: can it occur in non-atopics? Reid MJ, Schwietz LA, Whisman BA, Moss RB. N Engl Reg Allergy Proc. 1988 May-Jun; 9 (3): 225-32
The role of IgG subclass antibodies in chronic infection: the case of cystic fibrosis. Moss RB, N Engl Reg Allergy Proc. 1988 Jan-Feb; 9 (1): 57-61
Allergy evaluation in children: skin testing and RAST Moss RB, Am J Asthma Allergy Pediatr. 1988; 110 101-8
Assessment of validity of allergen reactivity with multiple skin prick testing, RAST, EAST, and rocket immunoelectrophoresi Eichler I, Gotz M, Jarisch R, Moss R. Allergy. 1988; 43 458-63
Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis Smith AL, Redding G, Doershuk C, Goldman D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Rubio T, Schwartz R, Thomassen MJ, Williams-Warren J, Weber A, Wilmott R, Wilson D, Yogev R.. J Pediatr. 1988; 1112 547-54
IgG subclass antibody markers in grass pollen immunotherapy. Moss RB, N Engl Reg Allergy Proc. 1987 Nov-Dec; 8 (6): 409-15
Hypergammaglobulinemia in cystic fibrosis. Role of Pseudomonas endobronchial infection. Moss RB, Chest. 1987; 91 (4): 522-6
Effect of total lymphoid irradiation on IgE antibody responses in rheumatoid arthritis and systemic lupus erythematosus. Terr AI, Moss RB, Strober S. J Allergy Clin Immunol. 1987; 80 (6): 798-802
Altered antibody isotype in cystic fibrosis: impaired natural antibody response to polysaccharide antigens. Moss RB, Hsu YP, Van Eede PH, Van Leeuwen AM, Lewiston NJ, De Lange G. Pediatr Res. 1987; 22 (6): 708-13
Performance characteristics of immunoenzymatic testing for total and specific immunoglobulin E. Comparison of conventional assay with a microtiter plate accelerated computerized procedure Moss RB, Hsu Y, Esrig S. Ann Allergy. 1987; 59 185-91
Interobserver variance in clinical scoring for cystic fibrosis Lewiston NJ, Moss RB, Hindi R, Rubinstein S, Sullivan MM. Chest. 1987; 91 878-92
IgE antibodies in young children with possible allergic symptoms Lewiston NJ, Hindi R, Hsu YP, Lewiston J, Moss RB. J Pediatr. 1987; 110 738-40
Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: correlation of rye group I antigen-specific IgG1 with clinical response. Moss RB, Hsu YP, Kwasnicki JM, Sullivan MM, Reid MJ. J Allergy Clin Immunol. 1987; 79 (2): 387-98
IgG subclass antibody markers in grass pollen immunotherapy Moss RB, Allergy Proceed. 1987; 8 409-15
Antibody and immune complex production in cystic fibrosis Moss RB, Pediatr Pulmonol. 1987; Suppl 1 95-8
Immune complexes in CF: keys to new clinical insight Lewiston NJ, Moss RB.. J Respir Dis. 1986; 7 60-6
Cow's milk allergy in breast fed infants. Role of allergen and breast milk secretory IgA antibody Machtinger S, Moss RB. J Allergy Clin Immunol. 1986; 77 341-7
Constipation and meconium ileus equivalent in cystic fibrosis Rubinstein S, Moss RB, Lewiston NJ. Pediatrics. 1986; 78 473-9
Generation and characterization of human monoclonal anti-Pseudomonas aeruginosa antibodies Larrick JW, Hart SM, Lippman D, Glembourtt M, Hsu YP, Moss RB. Strelkauskas A (ed), Human Hybridomas: Diagnostic and Therapeutic Applications. Marcel Dekker, Inc., New York. 1986; 65-80
IgG subclasses in respiratory disorders: cystic fibrosis Moss RB, Shakib F (ed), Basic and Clinical Aspects of IgG Subclasses. Monographs in Allergy, vol. 19. SW Karger, Basel. 1986; 202-9
Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. Reid MJ, Moss RB, Hsu YP, Kwasnicki JM, Commerford TM, Nelson BL. J Allergy Clin Immunol. 1986; 78 (4 Pt 1): 590-600
Supraventricular tachycardia in patients with cystic fibrosis. Sullivan MM, Moss RB, Hindi RD, Lewiston NJ. Chest. 1986; 90 (2): 239-42
Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency. Moss RB, Hsu YP, Sullivan MM, Lewiston NJ. Pediatr Res. 1986; 20 (5): 453-9
Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis. Moss RB, Hsu YP, Lewiston NJ, Curd JG, Milgrom H, Hart S, Dyer B, Larrick JW. Am Rev Respir Dis. 1986; 133 (4): 648-52
IgG subclasses in respiratory disorders: cystic fibrosis. Moss RB, Monogr Allergy. 1986; 19 202-9
In vitro expansion of human B cells for the production of human monoclonal antibodies Larrick JW, Dyer BJ, Senyk G, Hart SM, Moss RB, Lippman D, Jahnsen MC, Wang J, Weintraub H, Raubitschek AA. Engleman EG, Foung SKH, Larrick JW, Raubitschek AA (eds), Human Hybridomas and Monoclonal Antibodies. Plenum Press, NY. 1985; 149-65
Cystic fibrosis and neuroblastoma. Moss RB, Blessing-Moore J, Bender SW, Weibel A. Pediatrics. 1985; 76 (5): 814-7
Underestimation of specific immunoglobulin E by microtiter plate enzyme-linked immunosorbent assays. Reid MJ, Kwasnicki JM, Moss RB, Cheung NK. J Allergy Clin Immunol. 1985; 76 (2 Pt 1): 172-6
Allergic phenomena in cystic fibrosis Lewiston NJ, Moss RB. Shapira E, Wilson GB (eds), Immunological Aspects of Cystic Fibrosis. CRC Press Inc., Boca Raton. 1984; 125-47
Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. Ortolani C, Pastorello E, Moss RB, Hsu YP, Restuccia M, Joppolo G, Miadonna A, Cornelli U, Halpern G, Zanussi C. J Allergy Clin Immunol. 1984; 73 (2): 283-90
Allergy to semisynthetic penicillins in cystic fibrosis. Moss RB, Babin S, Hsu YP, Blessing-Moore J, Lewiston NJ. J Pediatr. 1984; 104 (3): 460-6
Sudden death in adolescent asthma. Rubinstein S, Hindi RD, Moss RB, Blessing-Moore J, Lewiston NJ. Ann Allergy. 1984; 53 (4): 311-8
Immunopathology of cystic fibrosis Moss RB, Shapira E, Wilson GB (eds), Immunological Aspects of Cystic Fibrosis. CRC Press Inc., Boca Raton. 1984; 5-27
Microtiter immunoenzymatic assay (micro-ELISA) for antigen-specific IgG4 subclass antibody. Hsu YP, Moss RB. Clin Rev Allergy. 1983; 1 (2): 231-6
Enzyme immunoassay for honeybee venom specific IgG4 Halpern GM, Moss RB, Hsu YP, Blessing J. Avrameas S (ed), Immunoenzymatic Techniques. Elsevier Science Publishers, Amsterdam. 1983; 395-401
A microtiter immunoenzymatic assay for antigen-specific IgG4 subclass antibodies Hsu YP, Moss RB.. Clin Rev Allergy. 1983; 1 233-6
Immunology of cystic fibrosis: immunity, immunodeficiency, and hypersensitivity. Moss RB, Lloyd-Still JD (ed), Textbook of Cystic Fibrosis. Wright-PSG Publishing Inc., Boston. 1983; 109-51
IgG4 antibody to Pseudomonas aeruginosa in cystic fibrosis Moss RB, Hsu YP, Leahy M, Halpern G. Kerr JW, Ganderton MA (eds), Proceedings of Invited Symposia, XII International Congress of Allergology and Clinical Immunology, Macmillan, London. 1983; 351-5
Isolation and characterization of circulating immune complexes in cystic fibrosis. Moss RB, Hsu YP. Clin Exp Immunol. 1982; 47 (2): 301-8
125I-Clq-binding and specific antibodies as indicators of pulmonary disease activity in cystic fibrosis. Moss RB, Hsu YP, Lewiston NJ. J Pediatr. 1981; 99 (2): 215-22
Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis. Moss RB, Lewiston NJ. Am Rev Respir Dis. 1980; 121 (1): 23-9
Chronic neuropathy presenting as a floppy infant with respiratory distress. Moss RB, Sriram S, Kelts KA, Forno LS, Lewiston NJ. Pediatrics. 1979; 64 (4): 459-64
The immunologic and clinical associations of the split products of C'3 in plasma in juvenile rheumatoid arthritis Miller JJ, Hsu YP, Moss RB, Olds L. Arth Rheum. 1979; 22 502-7
Cuirass ventilation in childhood neuromuscular disease O'Leary J, Moss RB, King R, Liebhaber M, Lewiston N. J Pediatr. 1979; 94 419-21